References:
1. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone associated proarrhythmic effect. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-35.
2. Connoly SJ. Evidence based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025-2034.
3. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace. 2014;16(January(1)):101-108.
4. Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(October (38)):2893-2962.
5. Shenthar J, Rachaiah JM, Pillai V et al. Incidence of drug-induced torsades de pointes with intravenous amiodarone. Indian Heart J. 2017 Nov-Dec;69(6):707-713.
6. Psirropoulos D, Lefkos N, Boudonas G et al. Incidence of and predicting factors for torsades de pointes during intravenous administration of amiodarone. Heart Drug.2001;1(4):186-191.
7. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic Mechanism of the Long QT Interval Syndromes and Torsade de Pointes. Ann Intern Med. 1995;122:701-14.
8. Nattel S, Talajic M, Quantz M, DeRoode M. Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel blocking activity. Circulation. 1987;76:442-9.
9. Schrickel JW, Schwab JO, Yang A, et al. Pro-arrhythmic effects of amiodarone and concominant rate-control medication. Europace.2006;8(May (6)):403-407.
10. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:D39-44.
Figure legends:
Fig.1 ECG on admission revealing rapid atrial fibrillation.
Fig.2 ECG showing episodes of TdP and markedly prolonged QT interval.
Fig.3 ECG with temporal pacemaker at 75 bpm.